AU2017359819B2 - FGFR4 inhibitor and preparation method and use thereof - Google Patents
FGFR4 inhibitor and preparation method and use thereof Download PDFInfo
- Publication number
- AU2017359819B2 AU2017359819B2 AU2017359819A AU2017359819A AU2017359819B2 AU 2017359819 B2 AU2017359819 B2 AU 2017359819B2 AU 2017359819 A AU2017359819 A AU 2017359819A AU 2017359819 A AU2017359819 A AU 2017359819A AU 2017359819 B2 AU2017359819 B2 AU 2017359819B2
- Authority
- AU
- Australia
- Prior art keywords
- group
- mmol
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- PPCNBJDEYKDMCY-ONEGZZNKSA-N COc(c(Cl)c1/C=C/Br)cc(OC)c1Cl Chemical compound COc(c(Cl)c1/C=C/Br)cc(OC)c1Cl PPCNBJDEYKDMCY-ONEGZZNKSA-N 0.000 description 1
- NRVIMVBMBICNGV-XGICHPGQSA-N COc(cc(c(Cl)c1/C(/F)=C/c2cnc(NC(COC3)C3NC(C=C)=O)nc2)OC)c1Cl Chemical compound COc(cc(c(Cl)c1/C(/F)=C/c2cnc(NC(COC3)C3NC(C=C)=O)nc2)OC)c1Cl NRVIMVBMBICNGV-XGICHPGQSA-N 0.000 description 1
- HNZRLCLPDYNOGD-IZZDOVSWSA-N COc1cc(/C=N/N)cc(OC)c1 Chemical compound COc1cc(/C=N/N)cc(OC)c1 HNZRLCLPDYNOGD-IZZDOVSWSA-N 0.000 description 1
- 0 COc1cc(C=C*)cc(OC)c1 Chemical compound COc1cc(C=C*)cc(OC)c1 0.000 description 1
- ZVRAHWAZBQUVSP-UHFFFAOYSA-N NC(C1CC1)O Chemical compound NC(C1CC1)O ZVRAHWAZBQUVSP-UHFFFAOYSA-N 0.000 description 1
- WWZQSGVGUXCQRC-IMJSIDKUSA-N N[C@@H](COC1)[C@H]1I Chemical compound N[C@@H](COC1)[C@H]1I WWZQSGVGUXCQRC-IMJSIDKUSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611012431.5 | 2016-11-17 | ||
| CN201611012431 | 2016-11-17 | ||
| PCT/CN2017/111634 WO2018090973A1 (zh) | 2016-11-17 | 2017-11-17 | Fgfr4抑制剂及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017359819A1 AU2017359819A1 (en) | 2019-06-20 |
| AU2017359819B2 true AU2017359819B2 (en) | 2020-05-28 |
Family
ID=62145242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017359819A Active AU2017359819B2 (en) | 2016-11-17 | 2017-11-17 | FGFR4 inhibitor and preparation method and use thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11008292B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3543227B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7063899B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102249632B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN109952290B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017359819B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3043948C (cg-RX-API-DMAC7.html) |
| IL (1) | IL266659B (cg-RX-API-DMAC7.html) |
| MX (1) | MX389403B (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ754218A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018090973A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201903845B (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL274274B2 (en) * | 2017-11-01 | 2023-11-01 | Guangdong Zhongsheng Pharmaceutical Co Ltd | Salt form and crystal form of compound as fgfr4 inhibitor and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016164703A1 (en) * | 2015-04-09 | 2016-10-13 | Eisai R & D Management Co., Ltd. | Fgfr4 inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101003514A (zh) | 2006-01-20 | 2007-07-25 | 上海艾力斯医药科技有限公司 | 喹唑啉衍生物、其制备方法及用途 |
| CN102731485B (zh) | 2011-04-02 | 2016-06-15 | 齐鲁制药有限公司 | 4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途 |
| CN109627239B (zh) | 2012-07-11 | 2021-10-12 | 缆图药品公司 | 成纤维细胞生长因子受体的抑制剂 |
| WO2014139145A1 (en) * | 2013-03-15 | 2014-09-18 | Hutchison Medipharma Limited | Novel pyrimidine and pyridine compounds and usage thereof |
| PH12016500676B1 (en) * | 2013-10-18 | 2022-07-20 | Eisai R&D Man Co Ltd | Pyrimidine fgfr4 inhibitors |
| WO2016115412A1 (en) | 2015-01-18 | 2016-07-21 | Newave Pharmaceutical Llc | Dual-warhead covalent inhibitors of fgfr-4 |
| AU2016248056B2 (en) | 2015-04-14 | 2020-07-23 | Eisai R&D Management Co., Ltd. | Crystalline FGFR4 inhibitor compound and uses thereof |
| IL274274B2 (en) * | 2017-11-01 | 2023-11-01 | Guangdong Zhongsheng Pharmaceutical Co Ltd | Salt form and crystal form of compound as fgfr4 inhibitor and preparation method thereof |
-
2017
- 2017-11-17 AU AU2017359819A patent/AU2017359819B2/en active Active
- 2017-11-17 EP EP17871196.6A patent/EP3543227B1/en active Active
- 2017-11-17 NZ NZ754218A patent/NZ754218A/en active IP Right Revival
- 2017-11-17 CN CN201780070537.7A patent/CN109952290B/zh active Active
- 2017-11-17 US US16/461,373 patent/US11008292B2/en active Active
- 2017-11-17 WO PCT/CN2017/111634 patent/WO2018090973A1/zh not_active Ceased
- 2017-11-17 KR KR1020197016780A patent/KR102249632B1/ko active Active
- 2017-11-17 JP JP2019526465A patent/JP7063899B2/ja active Active
- 2017-11-17 CA CA3043948A patent/CA3043948C/en active Active
- 2017-11-17 MX MX2019005723A patent/MX389403B/es unknown
-
2019
- 2019-05-15 IL IL266659A patent/IL266659B/en unknown
- 2019-06-13 ZA ZA2019/03845A patent/ZA201903845B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016164703A1 (en) * | 2015-04-09 | 2016-10-13 | Eisai R & D Management Co., Ltd. | Fgfr4 inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| US20200062716A1 (en) | 2020-02-27 |
| WO2018090973A1 (zh) | 2018-05-24 |
| IL266659B (en) | 2022-01-01 |
| JP2019537613A (ja) | 2019-12-26 |
| JP7063899B2 (ja) | 2022-05-09 |
| CN109952290A (zh) | 2019-06-28 |
| CA3043948C (en) | 2021-08-31 |
| MX389403B (es) | 2025-03-20 |
| EP3543227B1 (en) | 2020-12-30 |
| NZ754218A (en) | 2021-07-30 |
| EP3543227A1 (en) | 2019-09-25 |
| CA3043948A1 (en) | 2018-05-24 |
| AU2017359819A1 (en) | 2019-06-20 |
| IL266659A (en) | 2019-07-31 |
| US11008292B2 (en) | 2021-05-18 |
| EP3543227A4 (en) | 2019-10-30 |
| KR20190077085A (ko) | 2019-07-02 |
| MX2019005723A (es) | 2019-10-21 |
| KR102249632B1 (ko) | 2021-05-10 |
| CN109952290B (zh) | 2022-05-03 |
| ZA201903845B (en) | 2020-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3466929B1 (en) | Heterocyclic compounds useful as pdk1 inhibitors | |
| US10174056B2 (en) | Substituted pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | |
| EP3290418B1 (en) | Janus kinase (jak) inhibitors | |
| KR102359993B1 (ko) | 피리미도[5,4-b]인돌리진 또는 피리미도[5,4-b]피롤리진 화합물, 그의 제조방법 및 용도 | |
| KR20150128842A (ko) | 브로모도메인 억제제로서의 퓨로피리딘 | |
| ES2686747T3 (es) | Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirimidina y derivados de 2,3-dihidro-1H-imidazo[1,2-b]pirazol sustituidos como inhibidores de ROS1 | |
| KR102833011B1 (ko) | 푸로[3,4-b]피롤-함유 BTK 억제제 | |
| AU2017359819B2 (en) | FGFR4 inhibitor and preparation method and use thereof | |
| EP3849977B1 (en) | Improved method for the manufacture of 3-[(1s)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof | |
| KR20250053860A (ko) | Myc의 억제제 및 그의 용도 | |
| HK40004140B (en) | Fgfr4 inhibitor and preparation method and use thereof | |
| HK40004140A (en) | Fgfr4 inhibitor and preparation method and use thereof | |
| HK40053049B (en) | Improved method for the manufacture of 3-[(1s)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof | |
| HK40053049A (en) | Improved method for the manufacture of 3-[(1s)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof | |
| HK1244803B (zh) | 作为抗癌药物的取代的2-氢-吡唑衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |